182 related articles for article (PubMed ID: 12201855)
1. The bleeding edge of decision making in managed health care--Kaiser-Permanente's model for formulary development.
Campen D
Value Health; 2002; 5(5):383-9. PubMed ID: 12201855
[No Abstract] [Full Text] [Related]
2. Operation, formulary decision-making activities of a P & T Committee in a managed care setting.
Adams J; Richardson J
Hosp Formul; 1991 Apr; 26(4):291-4, 300-1. PubMed ID: 10109798
[TBL] [Abstract][Full Text] [Related]
3. Application of pharmacoeconomics to formulary decision making in managed care organizations.
Suh DC; Okpara IR; Agnese WB; Toscani M
Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
[TBL] [Abstract][Full Text] [Related]
4. The drug formulary decision-making process.
Brehany J; Cohen P; Sax MJ
Healthplan; 1999; 40(3):85-92. PubMed ID: 10538088
[No Abstract] [Full Text] [Related]
5. Formulary submission process catches on ... slowly.
Cross M
Manag Care; 2002 Nov; 11(11):32-6. PubMed ID: 12491856
[No Abstract] [Full Text] [Related]
6. The Academy of Managed Care Pharmacy's format for formulary submission.
Penna P
Manag Care Interface; 2001 Jun; 14(6):61-2. PubMed ID: 11432152
[No Abstract] [Full Text] [Related]
7. Increased pressures change P & T Committee makeup.
Cross M
Manag Care; 2001 Dec; 10(12):18-9, 23-4, 27-30. PubMed ID: 11794998
[No Abstract] [Full Text] [Related]
8. Raising the bar in the formulary decision process.
Navarro RP
Manag Care Interface; 1999 Jul; 12(7):51, 54. PubMed ID: 10539501
[No Abstract] [Full Text] [Related]
9. Will the Patient's Bill of Rights adversely affect pharmacy contracting?
Kenney JT
Manag Care Interface; 2000 Oct; 13(10):79, 81. PubMed ID: 11155653
[No Abstract] [Full Text] [Related]
10. The formulary decision-making process in a health maintenance organisation setting.
Shepherd MD; Salzman RD
Pharmacoeconomics; 1994 Jan; 5(1):29-38. PubMed ID: 10146864
[TBL] [Abstract][Full Text] [Related]
11. Kaiser Permanente's commitment to breastfeeding.
Baxter RJ
Breastfeed Med; 2014 Sep; 9(7):345-6. PubMed ID: 25117916
[No Abstract] [Full Text] [Related]
12. Rethinking formulary strategy: management and measurement considerations.
Nugent ME
Am J Manag Care; 1999 Sep; 5(9):1202-4. PubMed ID: 10621084
[No Abstract] [Full Text] [Related]
13. The case for a value-based formulary: striving for total lowest net cost.
Weart W; Bauman GR
Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
[TBL] [Abstract][Full Text] [Related]
14. The economics of lipid management.
Mullins CD
Manag Care; 2001 Nov; 10(11 Suppl):17-8; discussion 19-24. PubMed ID: 11761626
[No Abstract] [Full Text] [Related]
15. Kaiser Permanente's New Technologies Committee: an approach to assessing technology.
McGuire P
QRB Qual Rev Bull; 1990 Jun; 16(6):240-2. PubMed ID: 2120662
[TBL] [Abstract][Full Text] [Related]
16. Choosing the right PBM.
Brodsky KL
HMO; 1995; 36(3):107-9, 112. PubMed ID: 10166470
[TBL] [Abstract][Full Text] [Related]
17. Managed care guidelines for the economic evaluation of pharmaceuticals.
Langley PC; Martin RE
Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
[TBL] [Abstract][Full Text] [Related]
18. Formulary economics must consider costs beyond direct healthcare.
Exec Solut Healthc Manag; 1998 Aug; 1(6):16-7. PubMed ID: 10185383
[No Abstract] [Full Text] [Related]
19. The evolving role of the P&T committee: enhancing the health technology assessment process.
Tadlock C
Manag Care Interface; 2006 Feb; 19(2):14-5. PubMed ID: 16529077
[No Abstract] [Full Text] [Related]
20. Pharmacoeconomics: a managed care perspective.
Clouse JC
Top Hosp Pharm Manage; 1994 Jan; 13(4):54-9. PubMed ID: 10130684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
